All Blogs
Jan 05, 2023
Inspira and Terumo Signed Strategic Agreement; Cook Medical’s New Bipolar Electrodes Portfolio; Verana Health and Sight Sciences Collaborated on Glaucoma Research; Burning Rock’s OverC Multi-Cancer Detection Blood Test; Innova Vascular’s Thrombectomy System; liberDi’s Digital Dialysis System
Inspira Technologies Signed Strategic OEM Agreement with Terumo Cardiovascular On December 27, 2023, Inspira Technologies, a ground breaking respiratory support technology company, announced that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of...
Read More...
Jan 04, 2023
Insights Into the Evolving Landscape of the Ocular Implants Market
Vision loss or vision impairment is one of the major issues globally that can affect people of all ages. As per the WHO, Globally, about 2.2 billion people have a near or distance vision impairment. Moreover, in almost half of the cases, vision impairment could have been prevented or has yet to be addressed. It is ...
Read More...
Jan 03, 2023
Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen’s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound’s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics’ Briumvi
Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, GS-1811 (formerl...
Read More...
Aug 20, 2025
ENHERTU’s Rapid Rise: How the HER2-Targeting ADC Is Redefining Cancer Treatment with Back-to-Back Label Expansions
ENHERTU, a next-generation antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo/ AstraZeneca since March 2019, except in Japan, where Daiichi Sankyo maintains exclusive rights. It is worth noting that recently, in November 2024, Daiichi Sankyo and AstraZeneca were awarded the Galien Foundation 2024 Pri...
Read More...
Dec 30, 2022
Need of the Hour: Enhanced Strategies for PD-LID Treatment and Management
Parkinson’s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain’s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a...
Read More...
Dec 29, 2022
PAVmed-Novosound’s Partnership; J&J Acquires Abiomed; Approval to Sysmex’s Assay Kit to Identify Amyloid Beta (Aβ) Accumulation; SI-BONE Announced FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite Implant System; EOFlow’s Wearable Insulin Pump ‘EOPatch’; Icecure’s ProSense System, a Cryoablation Therapy
PAVmed Entered into a Partnership with Novosound for Ultrasound Imaging Technology On December 22, 2022, PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that the company has entered into a partnership with...
Read More...
Aug 26, 2026
How is the Active Implantable Medical Devices Market Evolving?
Active implantable medical devices (AIMDs) represent one of the most transformative categories of modern medical technology, combining electronics, materials science, and clinical medicine to deliver therapy or monitoring from within the human body itself. Unlike passive implants such as joint prostheses or vascula...
Read More...
Dec 27, 2022
Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC
FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be...
Read More...
Dec 26, 2022
Limbal Stem Cell Deficiency (LSCD): A Multifactorial Disease with Challenging Diagnosis and Treatment
Limbal Stem Cell Deficiency (LSCD) is a rare, progressive ocular surface disorder that results in conjunctivalization and neovascularization of the corneal surface. Ocular discomfort, reduced visual acuity, and photophobia are all symptoms of LSCD, which can be brought on by severe ocular surface illness. ...
Read More...
Dec 22, 2022
Medtronic’s Hugo Robotic-Assisted Surgery System Trial; Insightec’s Pivotal LIBERATE Clinical Trial; FDA Granted EMA for Thermo Fisher Scientific’s Monkeypox Test; Life Spine’s Trulift Lateral Expandable Spacer System & Lateral Pate System; Fujifilm & Inspirata Announces Asset Purchase Agreement; Abbott Launched SCS System for Chronic Pain
Medtronic Announced First Patient Enrolment for Hugo™ Robotic-Assisted Surgery System in US Clinical Trial On December 15, 2022, Medtronic, a global healthcare technology leader, announced that the first patient was enrolled in the Expand URO US clinical trial for the Hugo™ robotic-assisted surgery...
Read More...